Prospective multicenter study of the impact of carbapenem resistance on mortality in Pseudomonas aeruginosa bloodstream infections.
about
Mortality attributable to carbapenem-resistant Pseudomonas aeruginosa bacteremia: a meta-analysis of cohort studiesInfluence of carbapenem resistance on mortality of patients with Pseudomonas aeruginosa infection: a meta-analysisFitness cost of antibiotic susceptibility during bacterial infection.Impact of combination antimicrobial therapy on mortality risk for critically ill patients with carbapenem-resistant bacteremia.Pseudomonas aeruginosa AmpR: an acute-chronic switch regulator.Clinical outcomes associated with polymyxin B dose in patients with bloodstream infections due to carbapenem-resistant Gram-negative rodsInfluence of multidrug resistance and appropriate empirical therapy on the 30-day mortality rate of Pseudomonas aeruginosa bacteremia.Bacterial and clinical characteristics of health care- and community-acquired bloodstream infections due to Pseudomonas aeruginosa.Enhanced in vivo fitness of carbapenem-resistant oprD mutants of Pseudomonas aeruginosa revealed through high-throughput sequencing.Deciphering the Resistome of the Widespread Pseudomonas aeruginosa Sequence Type 175 International High-Risk Clone through Whole-Genome Sequencing.Carbapenem-Resistant Pseudomonas aeruginosa Bacteremia: Risk Factors for Mortality and Microbiologic Treatment Failure.Host and Pathogen Biomarkers for Severe Pseudomonas aeruginosa Infections.Global prevalence of carbapenem resistance in neutropenic patients and association with mortality and carbapenem use: systematic review and meta-analysis.Multiple-Drug Resistance in Burn Patients: A Retrospective Study on the Impact of Antibiotic Resistance on Survival and Length of Stay.Interplay Between Antibiotic Resistance and Virulence During Disease Promoted by Multidrug-Resistant Bacteria.Genomics and Susceptibility Profiles of Extensively Drug-Resistant (XDR) Pseudomonas aeruginosa from Spain.In Vivo Emergence of Resistance to Novel Cephalosporin-β-Lactamase Inhibitor Combinations through the Duplication of Amino Acid D149 from OXA-2 β-Lactamase (OXA-539) in Sequence Type 235 Pseudomonas aeruginosa.Pharmacokinetic/pharmacodynamic target attainment of intravenous β-lactam regimens against Gram-negative bacteria isolated in a Brazilian teaching hospital.Acute Inflammatory Response of Patients with Pseudomonas aeruginosa Infections: A Prospective Study.Nosocomial dissemination of VIM-2-producing ST235 Pseudomonas aeruginosa in Lithuania.Mortality burden related to infection with carbapenem-resistant Gram-negative bacteria among haematological cancer patients: a retrospective cohort study.Genetic markers of widespread extensively drug-resistant Pseudomonas aeruginosa high-risk clones.Biological markers of Pseudomonas aeruginosa epidemic high-risk clones.Multi-locus sequence typing (MLST) of non-fermentative Gram-negative bacilli isolated from bloodstream infections in southern Poland.Combination therapy for extensively-drug resistant gram-negative bacteria.Mechanisms leading to in vivo ceftolozane/tazobactam resistance development during the treatment of infections caused by MDR Pseudomonas aeruginosa.Comparative genomics of clinical strains of Pseudomonas aeruginosa strains isolated from different geographic sites
P2860
Q28068844-BAE8F0FD-9FD1-436F-8585-D179DB3FC207Q35673458-2CFBD43C-92E4-4769-BBC8-A314F1294A15Q35707529-E8F905B9-A462-412C-B291-0AA0EAA3C571Q35746258-AF86E0C8-51EB-4A14-9C16-A4654F94EB88Q35975439-FFEF05C0-274C-4472-88D2-19320041A598Q36158501-B8B0CB99-306C-422A-BAA0-4522316A67D6Q36172460-8D646B34-5D17-4B6D-82BD-AB620A773002Q37036553-A498E16F-F827-4713-900B-701AA47F8DBBQ37409391-D964BAED-4C74-47BD-A01F-559FEF6074FBQ37428703-C6910B91-6118-4F90-A927-A156F3AA860FQ37538614-B04E2EDF-DF11-4600-88CA-4055D1377907Q38856197-B1FEA405-59FF-453F-8E21-8D313A28FD5DQ39044923-FC4FBE1A-7AB9-4D96-ADB7-5DB12FBBFCEDQ39094392-26496422-79C4-4F39-A66A-AD29A442FE06Q39218893-4947505A-923E-45EB-B66E-FA9962FD6DA4Q40056971-C3F26287-2F58-4FC1-9D6B-1AB56DC24B3AQ40148490-D422F6FA-86FF-4438-A861-D462F9ACC1E5Q40375664-4E305719-2057-41AD-BCF7-902FBB17413DQ40501527-E880FB69-BFE1-486E-B5CA-66B1E08CD109Q40882363-F244C4F4-71BC-4B20-B0B8-C71219A37582Q41091116-4AA7B6E9-44D4-401A-BDC3-371CD65E590FQ41183478-A104F394-3B84-40D7-947C-85A2B2A6D4DAQ42249771-651F948E-33DB-49C9-9B7F-1F2EE3F5F465Q46302328-718EBFF1-9E4F-49C9-80F7-387394216F73Q47819621-70BB77F0-2993-4CB3-8FF1-884F6DA77849Q49921578-6346C24D-FFDA-43ED-B03D-82402DF5A1B1Q57799883-84DA53C6-B43C-4202-8A04-FA0356CC8C39
P2860
Prospective multicenter study of the impact of carbapenem resistance on mortality in Pseudomonas aeruginosa bloodstream infections.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
Prospective multicenter study ...... ginosa bloodstream infections.
@ast
Prospective multicenter study ...... ginosa bloodstream infections.
@en
type
label
Prospective multicenter study ...... ginosa bloodstream infections.
@ast
Prospective multicenter study ...... ginosa bloodstream infections.
@en
prefLabel
Prospective multicenter study ...... ginosa bloodstream infections.
@ast
Prospective multicenter study ...... ginosa bloodstream infections.
@en
P2093
P2860
P50
P356
P1476
Prospective multicenter study ...... ginosa bloodstream infections.
@en
P2093
Ana Granados
Antonio Oliver
Carmen Peña
Cristina Suarez
Fernando Rodríguez
Javier Murillas
Luis Martínez-Martínez
Manuela Aguilar
Mónica Gozalo
P2860
P304
P356
10.1128/AAC.05991-11
P407
P577
2011-12-12T00:00:00Z